77328-79-1Relevant academic research and scientific papers
Design, Synthesis, and Evaluation of Tetrahydropyrrolo[1,2-c]pyrimidines as Capsid Assembly Inhibitors for HBV Treatment
Li, Xiaolin,Zhou, Kai,He, Haiying,Zhou, Qiong,Sun, Ya,Hou, Lijuan,Shen, Liang,Wang, Xiaofei,Zhou, Yuedong,Gong, Zhen,He, Shibo,Jin, Huangtao,Gu, Zhengxian,Zhao, Shuyong,Zhang, Long,Sun, Chunyan,Zheng, Shansong,Cheng, Zhe,Zhu, Yidong,Zhang, Minghui,Li, Jian,Chen, Shuhui
, p. 969 - 974 (2017)
The discovery of novel tetrahydropyrrolo[1,2-c]pyrimidines derivatives from Bay41-4109 as hepatitis B virus (HBV) inhibitors is herein reported. The structure-activity relationship optimization led to one highly efficacious compound 28a (IC50 = 10 nM) with good PK profiles and the favorite L/P ratio. The hydrodynamic injection model in mice clearly demonstrated the efficacy of 28a against HBV replication.
DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR
-
Paragraph 0074; 0077; 0078; 0079, (2017/08/01)
Disclosed is a dihydropyrimido fused ring derivative as a HBV inhibitor, and in particular relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof.
